---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-285106"
form_type: "8-K"
ticker: "OSUR"
cik: "0001116463"
company_name: "ORASURE TECHNOLOGIES INC"
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:12:38.021718+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OraSure acquires Sherlock Biosciences for $5M upfront plus up to $20M milestones and royalties on CT/NG test

## Summary
- Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
- Two milestone payments up to $20M aggregate tied to regulatory approval of Sherlock's CT/NG test.
- Quarterly mid-single-digit royalties on CT/NG test net sales through 2034.
- Sherlock becomes wholly owned subsidiary; convertible notes, preferred, and common stock receive allocated consideration.
- Stock options terminated without payment; financial statements to be filed by amendment within 71 days.

## SEC filing metadata
- accession: 0001193125-24-285106
- form_type: 8-K
- ticker: OSUR
- cik: 0001116463
- company_name: ORASURE TECHNOLOGIES INC
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1116463/000119312524285106/0001193125-24-285106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1116463/000119312524285106/d884076d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-285106
- JSON: https://secwatch.observer/filing/0001193125-24-285106.json
- Plain text: https://secwatch.observer/filing/0001193125-24-285106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.